红日药业(300026) - 2025 Q3 - 季度财报

Financial Performance - Q3 2025 revenue was CNY 1,353,594,654.88, a decrease of 6.32% year-over-year[5] - Net profit attributable to shareholders was CNY 2,132,915.33, down 89.40% compared to the same period last year[5] - Basic earnings per share decreased by 85.71% to CNY 0.001[5] - Total operating revenue for the current period is approximately ¥4.15 billion, a decrease of 6.6% compared to ¥4.44 billion in the previous period[20] - Net profit for the current period is approximately ¥91.93 million, a decline of 52.2% from ¥192.40 million in the previous period[21] - Earnings per share (EPS) for the current period is ¥0.03, down from ¥0.06 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 10,758,345,758.27, a decline of 3.64% from the previous year[5] - The company reported a total asset of ¥10,758,345,758.27 as of September 30, 2025, down from ¥11,165,116,699.53 at the beginning of the period, indicating a decrease of approximately 3.65%[16] - Total liabilities decreased from ¥2,366,561,176.36 to ¥1,962,784,651.56, indicating a reduction of about 17%[18] - Total equity attributable to shareholders of the parent company is approximately ¥8.64 billion, slightly down from ¥8.64 billion in the previous period[19] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 536,836,636.49, an increase of 6.28%[5] - Cash flow from operating activities generated a net amount of approximately ¥536.84 million, an increase of 6.3% from ¥505.13 million in the previous period[22] - The ending cash and cash equivalents balance was $1.39 billion, up from $1.04 billion in the prior period[23] - The company reported a net increase in cash and cash equivalents of $113.02 million, contrasting with a decrease of $505.06 million in the previous period[23] Investments and Expenses - Investment income for the period was CNY -287.46 million, a decrease of 160.99% year-over-year[10] - Financial expenses decreased by 64.26% to CNY 10.05 million compared to the same period last year[10] - The company reported a decrease in research and development expenses to approximately ¥132.73 million, down from ¥154.10 million in the previous period[20] - The company’s long-term investments decreased from ¥12,964,808.38 to ¥10,160,633.03, a decline of approximately 21.5%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 96,308[12] - The total number of restricted shares increased to 265,626,359 from 240,731,655, with an addition of 24,894,704 shares during the period[14] - The company has not disclosed any related party relationships among the top shareholders[13] Tax and Fees - The company needs to pay a total of ¥33,838,200 for tax and late fees, which includes ¥25,166,000 in taxes and ¥8,672,200 in late fees[15] Other Financial Metrics - Other comprehensive income after tax for the current period is approximately -¥308.94 thousand, compared to -¥1.51 million in the previous period[22] - The company experienced a net foreign exchange loss of approximately -¥45.77 million, compared to -¥50.47 million in the previous period[21] - Net cash flow from investment activities was -$93.36 million, a decrease from -$160.19 million in the previous period[23] - Cash inflow from financing activities totaled $51.26 million, compared to $36.08 million in the prior period[23] - Total cash outflow from financing activities was $381.02 million, down from $886.19 million year-over-year[23] - The net cash flow from financing activities was -$329.76 million, an improvement from -$850.11 million in the previous period[23] Audit Status - The company has not audited its third-quarter financial report[24]